Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016:2016:2168753.
doi: 10.1155/2016/2168753. Epub 2016 Dec 26.

Subureteral Injection with Small-Size Dextranomer/Hyaluronic Acid Copolymer: Is It Really Efficient?

Affiliations
Clinical Trial

Subureteral Injection with Small-Size Dextranomer/Hyaluronic Acid Copolymer: Is It Really Efficient?

Iyimser Üre et al. Biomed Res Int. 2016.

Abstract

The aim of this study was to evaluate the clinical results of patients with vesicoureteral reflux, which were treated with subureteral injection of small-size (80-120 μm) dextranomer/hyaluronic acid copolymer (Dx/HA). Data of 75 children (105 renal units) who underwent STING procedure with small-size Dx/HA for the treatment of vesicoureteral reflux (VUR) in our clinic between 2008 and 2012 were retrospectively analyzed. Preoperative reflux grade and side, injection indication, postoperative urinary infections and urinary symptoms, voiding cystourethrogram, and renal scintigraphy results were evaluated. The success rate of the procedure was 100% in patients with grades 1 and 2 reflux, 91% in patients with grade 3 reflux, and 82.6% in patients with grade 4. Overall success rate of the treated patients was 97%. Endoscopic subureteric injection with Dx/HA procedure has become a reasonable minimally invasive alternative technique to open surgery, long-term antibiotic prophylaxis, and surveillance modalities in treatment of VUR in terms of easy application, low costs and complication rates, and high success rates. Injection material composed of small-size dextranomer microspheres seems superior to normal size Dx/HA, together with offering similar success with low cost.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
The success rates according to VUR grade (%).

Comment in

Similar articles

Cited by

References

    1. Biočić M., Todorić J., Budimir D., et al. Endoscopic treatment of vesicoureteral reflux in children with subureteral dextranomer/hyaluronic acid injection: a single-centre, 7-year experience. Canadian Journal of Surgery. 2012;55(5):301–306. doi: 10.1503/cjs.003411. - DOI - PMC - PubMed
    1. Sorensen M. D., Koyle M. A., Cowan C. A., Zamilpa I., Shnorhavorian M., Lendvay T. S. Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux. Pediatric Surgery International. 2010;26(5):509–513. doi: 10.1007/s00383-010-2558-9. - DOI - PubMed
    1. Puri P., Cascio S., Lakshmandass G., Colhoun E. Urinary tract infection and renal damage in sibling vesicoureteral reflux. Journal of Urology. 1998;160(3):1028–1030. doi: 10.1016/S0022-5347(01)62690-9. - DOI - PubMed
    1. Puri P., Kutasy B., Colhoun E., Hunziker M. Single center experience with endoscopic subureteral dextranomer/hyaluronic acid injection as first line treatment in 1,551 children with intermediate and high grade vesicoureteral reflux. Journal of Urology. 2012;188, supplement 4:1485–1489. doi: 10.1016/j.juro.2012.02.023. - DOI - PubMed
    1. Peters C. A., Skoog S. J., Arant B. S., Jr., et al. Summary of the AUA guideline on management of primary vesicoureteral reflux in children. The Journal of Urology. 2010;184(3):1134–1144. doi: 10.1016/j.juro.2010.05.065. - DOI - PubMed

Publication types